Position in EXEL
as of Mar 31, 2026
· filed Jun 1, 2026
Position Value
$328,580
-$444,493 QoQ
Shares Held
7,661
-56.6% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.24%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Caerus Investment Advisors, LLC holds $2,701,203 across 9 Biotechnology names. EXEL ranks #3 (12.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,666 | $1,287,218 | |
| 2 | INCY |
Incyte Corp
|
5,694 | $535,919 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
7,661 | $328,580 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
4,905 | $277,083 | |
| 5 | SRPT |
Sarepta Therapeutics, Inc.
|
9,854 | $214,423 | |
| 6 | ALDX |
Aldeyra Therapeutics, Inc.
|
11,455 | $19,358 | |
| 7 | FATE |
Fate Therapeutics Inc
|
14,569 | $17,482 | |
| 8 | CDXS |
Codexis, Inc.
|
10,580 | $17,245 |
All Filings in EXEL
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $328,580 | 7,661 | Shares | Sole | 2026-06-01 | |
| 2025-12-31 | $773,073 | 17,638 | Shares | Sole | 2026-02-12 | |
| No filing history on record for this holder in this stock. | ||||||